Ipsen: encouraging data on Cabometyx expected at ASCO


(CercleFinance.com) – Ipsen announces that encouraging data will be presented on its Cabometyx (cabozantinib), for a variety of cancer types at the annual meeting of the American Society of Clinical Oncology (ASCO 2022) to be held from 3 to June 7.

Data presented will include results in metastatic non-small cell lung cancer, as well as the established indications of advanced renal cell carcinoma and radioiodine refractory differentiated thyroid cancer.

“These data show that the therapeutic potential of Cabometyx as a key therapeutic option against a wide range of tumors continues to be realized,” says the French pharmaceutical company.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.


Twitter


Facebook


LinkedIn


E-mail





Source link -85